FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
Systemically administered mRNA aggregates (RNA-LPA) transfect lymphoreticular organs, inducing a massive cytokine/chemokine response that rapidly reprograms the tumor microenvironment while mobilizing dendritic cells/lymphocytes to elicit…
Neeraj Agarwal: The latest in the mHSPC prostate cancer / AUA24, cancer, MedscapeLIVE, mHSPC treatment, Neeraj Agarwal, OncoDaily, Oncology, prostate cancer,
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
The vote that caused Prime Minister David Cameron to resign today and prompted financial markets to plunge around the world had its roots at O’Hare…
Dave Feldman is a senior software engineer, entrepreneur and a citizen scientist. After starting a low-carb diet in 2015, Dave found that his cholesterol num…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Three members share their advice on how to plan your schedule, make connections, and enjoy your time at AM24.
The management of elderly patients diagnosed with acute myelogenous leukemia (AML) is complicated by high relapse risk and comorbidities that often preclude access to allogeneic…
In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow…